Shots:

• The vaccine has achieved strong rates of neutralizing antibody responses- in line with those measured in people who have recovered from COVID-19- in all adult age groups in a P-II study
• The results showed 95%-100% seroconversion following the second injection in all age groups (18-95yrs. old) & across all doses- with acceptable tolerability & no safety concerns. The high immune response following the single dose in patients with prior infection shows strong booster potential of the vaccine
• The companies are planning to start the P-III study in the coming weeks and are expecting the vaccine to be approved in Q4’21- following the positive P-III outcomes & regulatory reviews

  Ref: Sanofi | Image: Sanofi